Published by Josh White on 6th October 2021
(Sharecast News) - Massachusetts-based gene therapy company Voyager Therapeutics announced an agreement through which Pfizer could licence novel capsids generated from Voyager's RNA-driven 'TRACER', or 'Tropism Redirection of AAV by Cell-type-specific Expression of RNA' screening technology on Wednesday.